IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
August 2021 Vol.:22, Issue:1

Association Between Inflammatory Cytokines and Long Term Adverse Outcomes in Acute Coronary Syndrome: A Systemic Review

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

JOSNA JOSEPH*, M. P. SUBASHCHANDRAN[1], R. S. SREELEKSHMI[2], PRASHOB G.R.[3]

**Doctor of Pharmacy Student,*
[1]Professor, Department of Pharmaceutics,
[2]Assistant Professor, Department of Pharmacy Practice
3-Principal, Sree Krishna College of Pharmacy and Research Centre, Thiruvananthapuram, Kerala-695502, India.

Submitted: 25 July 2021
Accepted: 31 July 2021
Published: 30 August 2021

Keywords: Acute coronary syndrome, Major adverse cardiovascular events, Inflammatory Cytokines, Adverse events, Myocardial oxygen demand, Acute myocardial ischemia

ABSTRACT

Acute Coronary Syndrome (ACS) is a term that comprises all clinical syndromes compactible with acute myocardial ischemia causing from an imbalance between myocardial oxygen demand and supply. It was stated that the inflammatory cytokines are involved within the pathophysiology of Acute Coronary Syndrome and which is associated with major adverse cardiovascular events (MACE). We analyse the reviews including the studies involving the power of multiple cytokines to predict major adverse cardiovascular events in ACS patients with follow up of minimum one year. The main intention of this article is to produce a review which explains the association between inflammatory cytokines and long term adverse outcomes in acute coronary syndrome.

INTRODUCTION

In worldwide mortality rate Cardiovascular diseases are the primary causes, and also 50% of those deaths are associated with ACS[1,2]. Thus it is related to important morbidity and monetary burden, as admission to hospital happens in 20% of ACS patients inside one year[1,2,3]. Inflammation plays an important role not solely within the progression of hardening of the arteries, however additionally in mediating removal of death tissue following infarction and in shaping the repair processes that area unit essential for resolution of the acute myocardial infarction[4,5]. For this reason, there has been hefty interest in measurement markers of inflammation in ACS and their price in predicting major adverse viscous events (MACE) like death, perennial infarction , tubing occlusion, coronary failure and perennial angina[6,7].

The most wide studied biomarker of inflammation is CRP, whereas varied studies have identified in associate to degree of association between CRP and MACE, the connection isn't sufficiently prophetical for activity of CRP to be counseled by current tips[7,8]. An outsized variety of studies have additionally examined the connection between current levels of individual cytokines measured when the onset of ACS and MACE, thus the actual fact that cytokines have an additional direct relationship with coronary artery disease than CRP[9,10]. Therefore, cytokines is also higher markers to analyse than CRP.

Inflammation may be a complicated network response of multiple totally different cell sorts to associate degree injury like AMI, that involves associate degree altered expression of cell surface markers and secretion of an outsized numbers of cytokines and chemokines. Therefore, it is probably that activity of a non-specific single marker to characterise "inflammation" during this complicated setting to associate degree over-simplified approach. A chronic cohort study found assessment of multiple inflammatory biomarkers to be a stronger predictor of the semi-permanent risk of adverse events when put next to at least one marker approach[11]. This has additionally been according in alternative state like body part cancer and carcinoma.

Therefore, this systematic review aims to analyse whether or not, in an exceedingly population of ACS patients with multiple cytokines measured, characterisation of inflammation victimisation combined cytokines analyses as hostile one marker approach was superior for predicting MACE.

METHODS

Search Strategy:

The necessary articles for the review were collected using online publications via PubMed, NCBI, Medline, Medscape, Embase, Embase classic. The data collected from medline is from a time period of 2001 to 2021 written in English, and the other online data collection sites are also used during this time period. Various keywords were used to collect the detailed data such as: myocardial infraction, ST segment elevation angina, ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, cytokines inflammation, long term adverse effects.

In this review, the full text of the related publications were obtained and analysed in order not to miss any relevant articles. Titles and abstracts are also reviewed, and the review is prepared based on the full analysis.

INCLUSION AND EXCLUSION CRITERIA

Inclusion Criteria:

The data in which blood samples collected within 7 days of symptom onset and analysed, inflammatory cytokines and chemokines were measured which included with MACE and one year of follow up should be done[1].

Exclusion Criteria:

Studies conducted via in vitro were excluded; in vitro studies refers to the studies of biological properties that are done in test tube rather than in humans or animals[1]. Recent MI, ischemic cerebrovascular stroke, within the last 3 months of treatment, recent acute infectious diseases, acute immunological diseases where excluded[12,13,14,15,16].

INFLAMMATORY CYTOKINES IN ACS

Ehrin.et.al performed a cohort study with 458 patients with ACS and followed up for 2yrs and thus these datas were analysed[17].

Table 1: Pathophysiological contributions of cytokines related to the various clinical data

Cytokines	Strength of Clinical Data	Pathophysiological Contributions
IL-6	Multiple cohort	Induction of acute-phase response
MCP-1	Single cohort	Monocyte migration, Activation of tissue factor
TNF-α	Case control	Myocardial dysfunction and remodeling
IL-18	Single cohort	Expression of interferon-γ
IL-10	Single cohort	Anti-inflammatory

Cytokines are the pleiotropic protiens that regulate the activity of leukocyte. Cytokines such as interleukin-1 (IL-1) and interleukin-6 (IL-6) increases the production of reactive protiens in the acute phase. The clinically implicated biomarkers of ACS are IL-6 & monocyte chemoattractant protein-1(MCP-1)[17].

Interleukin-6

Interleulin-6 (IL-6) is an omnipresent protein, the presence of that is crucial for corpuscle and epithelium cell activation. IL-6 additionally promotes production of viscous acute-phase reactants, as well as CRP[17]. IL-6 is expressed at the shoulder region of arterial sclerosis plaques and should increase plaque instability by driving expression of matrix metallo-proteinases, MCP-1, and tumour tissue (TNF)-α[10].



Figure 1: The involvement of interleukin-6 in the pathogenesis of acute coronary syndrome.

Patients with ACS have redoubled current levels of IL-6 compared with those patients who have stable angina. Among patients with unstable angina[12,17,18], a rise in IL-6 levels that occurred forty eight hours once admission compared with the admission price was related to the combined finish purpose of death, myocardial infarction (MI), or refractory angina[19]. Within the Fragmin or early Revascularization throughout instability in artery disease (FRISC-II) study, elevated IL-6 (>5 ng/L) was related to higher 6 and 12 months mortality and was additive to and freelance of viscous troponin T rate. Elevated IL-6 levels conjointly known a subgroup of patients who has the benefit of mortality. These results recommend that elevated level of IL-6 could determine patients with a lot of severe index event, thus they will benefit of aggressive treatment. Currently the massive time unit variations in IL-6 levels and lack of supportive studies limit the applications of IL-6 as a biomarker in ACS.

MCP- I = monocyte chemotactic protein- I, MMPs = matrix metalloproteinases, TNF-α = tumor necrosis factor-α, VSMC = vascular smooth muscle cell.

Elbadwy TH et.al conducted a study with 60 patients admitted with ACS and the categorise them randomly to 3 groups: including group-1 for unstable angina, group 2 for STEMI with successful thrombolytic therapy and group-3 for STEMI with failed thrombolytic therapy[19,20,21,22.23]. Additionally, they added a 4th group with healthy control patients. Blood levels of CRO, cardiac troponin 1, IL-6 were analysed. Thus, by this study they analysed that atherosclerosis is currently considered as systemic inflammatory disease and Interleukin-6 is an important inflammatory cytokine. IL-6 levels were increased in group-2 and there was a positive correlation between CRP and IL-6 in group-3 patients; IL-6 levels did not correlate with troponin level in any of ACS patients[24,25,26].

Monocyte Chemoattractant Protein-1

MCP-1 is a chemokine that activates mononucleate phagocytes by promoting leukocyte endothelium binding and migration to sites of inflammation. As per the pathophysiological role in ACS, inhibition of MCP-1 communication during a mouse model of MI improved survival at four weeks and additionally improved left bodily cavity perform[12].

In the Orbofiban in patients with Unstable Coronary Syndromes (OPUS), Thrombolysis in myocardial infarction (TIMI) sixteen trial, MCP-1 level >238 pg/mL was related to hyperbolic risk of death or MI when ten months, even when adjustment for ancient risk factors[27]. Measuring of MCP-1 within the sinus blood of patients with unstable angina, an association between MCP-1 levels were demonstrated and therefore the extent of coronary hardening of the arteries as assessed by the coronary angiogram[28]. Thus, the levels of MCP-1 is primarily a surrogate for hardening of the arteries burden and thus MCP-1 remains as the promising therapeutic target with an important pathophysiological role in atherothrombosis.

Other Cytokines

TNF-α may be a pro-inflammatory protein involved in heart muscle pathology and transforming once ACS[27,29], within the CARE (Cholesterol And Recurrent Events) trial of patients with a recent MI, those that veteran a perennial MI or viscous death had higher levels of TNF-α at study enrollment than matched controls.

IL-18 promotes expression of interferon-γ, a intermediator of plaque progression. Administration of exogenous IL-18 markedly will increase lesion size in an exceedingly mouse model of atherosclerosis[30,31]. IL-18 mRNA is expressed at higher levels in unstable

human arteria plaques relative to stable plaques, that suggests that IL-18 conjointly mediates later events in plaque stability and ultimate disruption[31,32]. Thus in an exceedingly prospective study of patients with unstable angina, who were undergoing coronary angiography, patients with IL-18 levels within the fourth grade (>77.7 pg/mL) had a markedly redoubled risk of vas death throughout long-run follow-up; an identical association was conjointly ascertained in patients with stable angina[33,34].

Interleukin-10 is not usual in proposed ACS biomarkers. In the CAPTURE study it is identified that patients with elevated CRP and IL-10 has low risk of nonfatal MI or death when compared with patients of elevated CRP but no elevation in IL-10; thus from this study it assume that IL-10 is protective against proinflammatory cytokines in ACS[35,36].

Long term adverse effects-ACS

Stepinska J et.al conducted a study in 345 patients among NSTEMI and STEMI were separately studied. Thus, they analysed the time of hospital administration percutaneous coronary intervention. From the 2 year follow up it is concluded that they have increased risk of cardiovascular and bleeding problems in patients with both NSTEMI and STEMI. NSTEMI patients on oral anticoagulant experienced prolonged time of intervention, lower rates of thrombolysis in MI (TIMI) flow and prolonged hospitalization[36,37].

MACE outcomes

Six studies found a big association between individual cytokines and MACE, either by univariate or statistical procedure[38,39,40.41,42,44]. Four of the 5 studies that created a hazard magnitude relation (HR) for IL-6 had values higher than 1.00[38,40,41,42,44] and 3 of these HRs were statistically important, indicating that IL-6 is a risk issue for MACE[39.40,44]; there have been mixed findings for IL-10, with five hundredth of the studies showing that the biomarker was protecting for MACE. Kaski et al. found IL-18 to be a risk issue for MACE, however a similar protein had a time unit below 1.00 for death and MI alone. Thus 2 studies that assessed IL-18 found a odds magnitude relation (OR) and a time unit per unit modification higher than 1.00[38,39,40,43]. **Table-2** summarises the statistically important findings found for the clinical endpoints of the studies.

Table 2: The statistically important findings found for the clinical endpoints of the studies

Endpoints	Combined Cytokine Analyses	Author
Combination of all cause death & MI	No joint analysis conducted	Simon T, et al.
All-cause death	Punished reversion analysis showed that 32 markers and GDF-15 + TRAIL-R2 alone had ROC AUCs of 0.85.	Skau E, et al.
Primary endpoint: Combination of all-cause death, MI, UA, PCI, & CABG Secondary endpoint: Combination of death & MI	No joint analysis conducted	Kaski JC, et al.
Combination of all-cause death, MI, stroke & TLR	No joint analysis conducted	Yu CW, et al.
Combination of repeated angina, MI, death, new revascularisation, & HF	Higher rank tally (with all 27 biomarkers) was related with MACE, F = 5.07; ROC curve analysis: Score of >13 cytokine levels beyond the median was a better analyst of MACE, with an AUC 0.72	Novo G, et al.
Combination of all-cause death & HF	No joint analysis conducted	Valgimigli M, et al.

Note: All the standards are statistically significant ($p \leq 0.05$).MI-myocardial infarction, GDF-15 - growth differentiation factor 15, TRAIL-R2: tumour necrosis factor-related apoptosis-inducing ligand receptor 2, UA- unstable angina, ROC- reciever operative characteristics, AUC-area under curve, CABG -coronary artery bypass graft, PCI- percutaneous coronary intervention, TLR- target lesion revascularisation, HF-heart failure, F - analysis of variance (ANOVA) F value, IL- interleukin, OR- odds ratio

The 8 studies that conducted a statistical procedure created changes for a range of potential confounders, supported what was found to be statistically important within the univariate analysis. Three of the 8 studies that measured individual cytokines on statistical procedure found that a little of these cytokines were considerably related to MACE[38,40,44]. Skau et al. and Chalikias et al. used many models adjusted for various teams of confounders[37,41]. Skau et al. had 4 models: one for age and sex alone; one for ancient risk factors for MACE; one for age, sex and biomarkers together with growth differentiation factor-15 (GDF-15), and path receptor-2 (TRAIL-R2); and a final model together with ancient risk factors and therefore the hand-picked biomarkers. All four models created high space underneath the curves (AUCs) from receiver operator curves starting from 0.79 for the model adjusting for less than age and sex, to 0.88 for the model adjusting for each ancient risk factors and therefore the hand-picked biomarkers. Chalikias et al. had 4 models primarily based on: clinical factors that were important on univariate analysis, lipid-related risk factors, MACE-related risk factors and medications. Out of those 4 models, IL-10 and IL-18 separately were solely considerably related to MACE in one or 2 of those models, whereas a combined IL-18/IL-10 magnitude relation was considerably related to MACE all told models[45].

DISCUSSION

In this systematic review, substantial heterogeneousness was ascertained in methodology together with the cytokines and chemokine studies, temporal order of blood assortment, definition of MACE, length of follow-up, and methodology of applied math analysis. All studies had either acceptable or poor internal validity, with most giving no clear explanation behind the selection of cytokines studied and a typically poor news on the validation of cohort size. However, all those studies that did a multi-marker analysis showed a major applied math association with MACE.

CONCLUSION

Even though some studies have analysed important associations between individual cytokines and MACE, we tend to found mixed associations from the various studies enclosed during this review. However, a joint analysis of multiple cytokines could have more association with MACE. This review highlights some cracks within the current body of proof on the connection between inflammatory cytokines and MACE in ACS patients, showing that there is sizeable non uniformity in strategies and results, like protein choice, blood

assortment times and cohort sizes. We might suggest future studies to supply a principle for his or her protein choice and be adequately hopped-up to find a clinically important distinction in fitly outlined MACE outcomes. Various studies were needed to identify the importance of the time of blood assortment. New strongly designed prospective studies that addresses the particular insufficiencies of past studies, those may need to check whether a multi-marker approach is also a big choice. Various investigations are needed to identify that which set of markers creates associate degree ideal panel and which methodology is most correct for merging the markers.

REFERENCES

1. Kristono GA, Holley AS, Lakshman P, Brunton-O'Sullivan MM, Harding SA, Larsen PD. Association between inflammatory cytokines and long-term adverse outcomes in acute coronary syndromes: A systematic review. Heliyon 2020; 6(4):e03704.
2. Benjamin E.J, Muntner P, Alonso A, Bittencourt M.S, Callaway C.W, Carson A.P, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
3. Kolansky D.M. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am. J. Manang. Care.2009;15(2 Suppl):S36–41.
4. Ruparelia N, Chai J.T, Fisher E.A, Choudhury R.P. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat. Rev. Cardilol. 2016;14:133.
5. Ong S.-B, Hernández-Reséndiz S, Crespo-Avilan G.E, Mukhametshina R.T, Kwek X.-Y, Cabrera-Fuentes H.A, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol. Therapeut. 2018;186:73–87.
6. Kip K.E, Hollabaugh K, Marroquin O.C, Williams D.O. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J. Am. Coll. Cardilol. 2008;51(7):701–707.
7. Krintus M, Kozinski M, Kubica J, Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit. Rev. Clin. LabSci. 2014;51(5):263–279.
8. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int. J. Cardiol. 2013;168(6):5126–5134.
9. Woods A, Brull D, Humphries S, Montgomery H. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000; 21: 1574–1583.
10. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Konaven P, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Circulation. 2000; 101: 1372–1378.
11. Biasucci L, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996; 94: 874–877.
12. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. JAMA. 2001; 286: 2107–2113.
13. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, *et al*. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004; 110:2032-8.
14. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990; 82(Suppl):38-46.
15. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6:131-8.
16. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, *et al*. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 1990; 85:1896-904.

17. Ehrin J. Armstrong, David A. Morrow, Marc S. Sabatine. Inflammatory biomarkers in Acute Coronary Syndrome.Circulation. 2006;e72-e75.
18. Biasucci L, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi A, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999; 99: 2079–2084.
19. Elbadawy TH, Mahrous AA, El Samnody HH. The relation between interleukin-6 and different categories of acute coronary syndrome. Res Opin Anesth Intensive Care 2015;2:7-15.
20. Mach F, Schönbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, *et al*. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154:229-38.
21. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, *et al*. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108:512-5.
22. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, *et al.* C-reactive protein in cardiovascular disease. JAMA 2008; 294:2866-90.
23. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-62.
24. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996; 17:64-102.
25. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993; 77:1690-4.
26. de Lemos J, Morrow D, Sabatine M, Murphy S, Gibson M, Antman E, McCabe C, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003; 107: 690–695.
27. Serrano-Martinez M, Palacios M, Lezaun R. Monocyte chemoattractant protein-1 concentration in coronary sinus blood and severity of coronary disease. Circulation. 2003; 108: e75.
28. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial remodeling. Circ Res. 2004; 94: 1543–1553.
29. Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of coronary events after myocardial infarction. Circulation. 2000; 101: 2149–2153.
30. de Nooijer R, von der Thusen J, Verkleij C, Kuiper J, Jukema J, van der Wall E, et al. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol. 2004; 24: 2313–2319.
31. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104: 1598–1603.
32. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; 106: 24–30.
33. Heeschen C, Dimmeler S, Hamm C, Fichtlscherer S, Boersma E, Simoons M, et al. Serum level of the anti-inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003; 107: 2109–2114.
34. Brown D, Breit S, Buring J, Fairlie D, Bauskin A, Liu T, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002; 359: 2159–2163.
35. Pai J, Pischon T, Ma J, Manson J, Hankinson S, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351*:* 2599–2610.
36. Stepinska J, Wojtkowska I, Annemans L, Danchin N, Pocock SJ, de Werf FV, et al. Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. Curr Vasc Pharmacol. 2020;18(1):92-99.
37. Skau E, Henriksen E, Wagner P, Hedberg P, Siegbahn A, Leppert J. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. Eur. J. Prev. Cardiol. 2017;24(15):1576–1583.

38. Novo G, Bellia C, Fiore M, Bonomo V, Pugliesi M, Giovino M, et al. A risk score derived from the analysis of a cluster of 27 serum inflammatory cytokines to predict long term outcome in patients with acute myocardial infarction: a pilot study. Ann. Clin. Lab. Sci. 2015;45(4):382–390.
39. Yu C.W, Choi S.-C, Hong S.J, Choi J.-H, Park C.Y, Kim J.-H, et al. Cardiovascular event rates in patients with ST-elevation myocardial infarction were lower with early increases in mobilization of Oct4highNanoghigh stem cells into the peripheral circulation during a 4-year follow-up. Int. J. Cardiol. 2013;168(3):2533–2539.
40. Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur. Heart J. 2013;34(8):570–577.
41. Chalikias G.K, Tziakas D.N, Kaski J.C, Kekes A, Hatzinikolaou E.I, Stakos D.A, et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int. J. Cardiol. 2007;117(3):333–339.
42. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction, the cytokine-activation and long-term prognosis in myocardial infarction (C-alpha) study.Circulation.2005;111(7):863–870.
43. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, *et al.* A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92:1355-74.
44. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
45. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 1988; 60:459-64.